Stock Track | Ardelyx Soars 7.72% Pre-Market on China Approval of Tenapanor for Hyperphosphatemia

Stock Track
02-26

Ardelyx Inc. (ARDX) shares surged 7.72% in pre-market trading on Wednesday after the company announced that its collaboration partner, Fosun Pharma, received approval from China's Center for Drug Evaluation for tenapanor (marketed as Wan Ti Le) to control serum phosphorus levels in dialysis patients with chronic kidney disease (CKD).

This approval triggers a $5 million milestone payment to Ardelyx from Fosun Pharma under their licensing agreement. Ardelyx is also eligible to receive additional developmental and commercialization milestones of up to $100 million, as well as tiered royalty payments on net sales ranging from the mid-teens to 20 percent.

Tenapanor, a first-in-class phosphate absorption inhibitor, has the potential to address a significant unmet need in China, where approximately 76% of over one million patients on maintenance hemodialysis suffer from hyperphosphatemia, and the rate of achieving target phosphate levels is low.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10